WaveMan
WaveMan · Company
ICLR · Icon Plc
> Search tickers & screens ⌘K
LIVE
← All companies

ICLR Icon (ICLR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Services-commercial physical & biological research · CIK 0001060955
Quote by TradingView
Form 144 · 12
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
234
13F, latest reported quarter
Conversions, 180 days
14
Codes C/M, not in net · $1.7M priced

What the filings say about ICLR

Insiders, 180 days
-$4.1M net sold
10 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 2 sold
Latest: sale, 2026-08-14
Planned sales (Form 144), 90 days
$4.0M
12 notices

Icon insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ICON PLC insiders sold a net $4.1M of stock across 42 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Lyons Emer
Chief Accounting Officer
SELL
2026-10-26 SECtraded 2026-10-23
42
$7.6K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.4% of the 1,220 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Lyons Emer sold about $7.6K of ICLR on Oct 23, 2026; 234 funds added in the latest 13F quarter.
Lyons Emer
Chief Accounting Officer
SELL
2026-10-26 SECtraded 2026-10-23
81
$14.7K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 7.1% of the 1,139 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Lyons Emer sold about $14.7K of ICLR on Oct 23, 2026; 234 funds added in the latest 13F quarter.
Lyons Emer
Chief Accounting Officer
SELL
2026-10-26 SECtraded 2026-10-23
43
$7.8K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.9% of the 1,096 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Lyons Emer sold about $7.8K of ICLR on Oct 23, 2026; 234 funds added in the latest 13F quarter.
Lyons Emer
Chief Accounting Officer
SELL
2026-10-26 SECtraded 2026-10-23
52
$9.5K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 5.0% of the 1,044 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Lyons Emer sold about $9.5K of ICLR on Oct 23, 2026; 234 funds added in the latest 13F quarter.
Lyons Emer
Chief Accounting Officer
SELL
2026-10-26 SECtraded 2026-10-23
54
$10.0K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 5.5% of the 990 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Lyons Emer sold about $10.0K of ICLR on Oct 23, 2026; 234 funds added in the latest 13F quarter.
42 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 37 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.1M over 180 days
-$4.1M over 90 days
below 77% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
234 funds bought in last quarter
more than 92% of Pharma & Biotech
Revenue
+0.8% year over year
below 52% of Pharma & Biotech
Margin
2.8% net margin
more than 76% of Pharma & Biotech
Buybacks
$750.0M repurchased, FY to 2025-12-31
more than 89% of Pharma & Biotech
Short interest
3.6% of the float short (float per yahoo 2026-10-26) · 2.5 days to cover · settled 2026-09-30
below 56% of Pharma & Biotech
What changed in the last 30 days
Oct 26Chief Accounting Officer Lyons Emer sold $49.6K (Oct 23)

Watch ICLR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+2.1%12M
-56%-33%-10%+13%2025-102025-122026-022026-042026-062026-082026-10 2026-09-16 · CLIMAX JOHN DR sold $875.9K2026-09-17 · Murphy Ronan Martin sold $875.9K2026-09-17 · McCague Eugene Pacelli sold $569.6K2026-08-11 · Murray Ciaran sold $309.2K2026-08-11 · Clerkin Nigel Bernard John sold $261.7K2026-08-11 · O'Neill Julie sold $105.6K2026-08-11 · CLIMAX JOHN DR sold $97.2K2026-08-11 · Grais Linda sold $97.0K2026-08-11 · Murphy Ronan Martin sold $97.0K2026-08-11 · McCague Eugene Pacelli sold $97.0K2026-08-11 · Whitaker Anne Clem sold $97.0K2026-08-11 · Murray Ciaran sold $49.9K2026-08-10 · Balfe Barry Edward sold $49.8K2026-08-11 · Murray Ciaran sold $45.6K2026-08-11 · Clerkin Nigel Bernard John sold $42.4K2026-08-11 · Clerkin Nigel Bernard John sold $38.6K2026-08-11 · Murray Ciaran sold $35.1K2026-08-11 · Clerkin Nigel Bernard John sold $29.8K2026-08-11 · O'Neill Julie sold $17.2K2026-08-11 · Grais Linda sold $15.9K2026-08-11 · Murphy Ronan Martin sold $15.7K2026-08-11 · McCague Eugene Pacelli sold $15.7K2026-08-11 · Whitaker Anne Clem sold $15.7K2026-08-11 · CLIMAX JOHN DR sold $15.6K2026-08-11 · O'Neill Julie sold $15.5K2026-10-23 · Lyons Emer sold $14.7K2026-08-11 · CLIMAX JOHN DR sold $14.3K2026-08-11 · Murphy Ronan Martin sold $14.3K2026-08-11 · McCague Eugene Pacelli sold $14.3K2026-08-11 · Whitaker Anne Clem sold $14.3K2026-08-11 · Grais Linda sold $14.2K2026-08-10 · Balfe Barry Edward sold $12.9K2026-08-11 · O'Neill Julie sold $12.1K2026-08-11 · CLIMAX JOHN DR sold $11.1K2026-08-11 · Grais Linda sold $11.1K2026-08-11 · Murphy Ronan Martin sold $11.1K2026-08-11 · McCague Eugene Pacelli sold $11.1K2026-08-11 · Whitaker Anne Clem sold $11.1K2026-10-23 · Lyons Emer sold $10.0K2026-10-23 · Lyons Emer sold $9.5K2026-10-23 · Lyons Emer sold $7.8K2026-10-23 · Lyons Emer sold $7.6K2026-09-17 · RONAN MARTIN MURPHY filed to sell $875.9K2026-09-17 · EUGENE PACELLI MCCAGUE filed to sell $569.6K2026-09-16 · JOHN CLIMAX filed to sell $875.9K2026-08-11 · JOHN CLIMAX filed to sell $138.2K2026-08-11 · NIGEL CLERKIN filed to sell $372.5K2026-08-11 · LINDA SUE GRAIS filed to sell $138.2K2026-08-11 · CIARAN MURRAY filed to sell $439.8K2026-08-11 · JULIE ANN O'NEILL filed to sell $150.3K2026-08-11 · RONAN MARTIN MURPHY filed to sell $138.2K2026-08-11 · EUGENE PACELLI MCCAGUE filed to sell $138.2K2026-08-11 · ANNE WHITAKER filed to sell $138.2K2026-08-10 · BARRY EDWARD BALFE filed to sell $62.7K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ICLR: institutional holders (13F)

13F holdings, latest reported quarter
Artisan Partners Limited Partnership
8,636,406 sh
$1.5B
WELLINGTON MANAGEMENT GROUP LLP
5,320,054 sh
$924.1M
FMR LLC
5,271,321 sh
$915.7M
Invesco Ltd.
5,264,236 sh
$914.5M
HARRIS ASSOCIATES L P
4,468,146 sh
$776.2M

Congress trades in ICLR

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Kevin Hern
Sold 2026-08-14 · disclosed 18 days later
$15,001 - $50,000
Kevin Hern
Sold 2026-03-05 · disclosed 29 days later
$100,001 - $250,000
Julia Letlow
Sold 2026-02-12 · disclosed 28 days later
$1,001 - $15,000
John James
Sold 2024-09-04 · disclosed 2 days later
$1,001 - $15,000
John James
Bought 2024-06-12 · disclosed 82 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ICLR planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
RONAN MARTIN MURPHY
Filed 2026-09-17
$875.9K
EUGENE PACELLI MCCAGUE
Filed 2026-09-17
$569.6K
JOHN CLIMAX
Filed 2026-09-16
$875.9K
JOHN CLIMAX
Filed 2026-08-11
$138.2K
NIGEL CLERKIN
Filed 2026-08-11
$372.5K

ICLR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Frank Value Fund
$2.3M position · as of 2026-06-30
6.4%
iShares MSCI Ireland ETF
$4.3M position · as of 2026-05-31
6.0%
Brown Advisory International Value Select ETF
$5.3M position · as of 2026-06-30
4.9%
Touchstone ETF Trust-Touchstone International Equity ETF
$4.7M position · as of 2026-06-30
4.3%
LYRICAL INTERNATIONAL VALUE EQUITY FUND
$1.3M position · as of 2026-05-31
3.5%
Brown Advisory Sustainable Value ETF
$12.4M position · as of 2026-06-30
3.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.1M sold by insiders over 180 days, 234 funds added last quarter, $4.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ICLR financials

Revenue growth
+0.8%
XBRL, annual
Net margin
2.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$8.3B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+0.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$883.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.23x
long-term 2026-06-30 plus current 2021-09-30 (57 months older than the period end); equity 2026-06-30
Cash flow to debt
0.49x
TTM operating cash flow over long-term 2026-06-30 plus current 2021-09-30 (57 months older than the period end)
Return on equity
+0.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+0.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
+2.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
353.42x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$15.3B
market value at close 2026-10-26 on 2025-12-31 shares, plus long-term 2026-06-30 plus current 2021-09-30 (57 months older than the period end), minus cash 2026-06-30
FCF yield
+6.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing EPS growth -95%, PEG needs growth
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$8.3B$8.3B$8.1B$7.7B
Operating income$442.8M$1.0B$904.7M$795.2M
Net income$229.3M$739.1M$554.2M$505.3M
EPS (diluted)2.908.906.706.13
Operating cash flow$1.0B$1.3B$1.2B$563.3M
Cash$647.3M$538.8M$378.1M$288.8M
Long-term debt$2.9B$3.4B$3.7B$4.6B
Buybacks$750.0M$500.0M$0$100.0M
SEC XBRL, fiscal years, as known on 2026-10-28

ICLR Stock Sonar score 6/7 axes

Find similar shapesCompare

ICLR ranks highest on profitability (83rd percentile) and financial health (65th), and lowest on insider conviction (10th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
83
Inputs
  • Return on equity+0.4% · 81 pct, sector of 545
  • Return on assets+0.3% · 82 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed+2.2% · 87 pct, sector of 576
Financial health
65
Inputs
  • Debt to equity0.23x · 42 pct, sector of 352
  • Cash flow to debt0.49x · 88 pct, sector of 371
Growth
63
Inputs
  • Revenue growth, YoY+0.8% · 48 pct, sector of 505
  • Backlog growth, YoY+9.0% · 77 pct, sector of 40
Insider conviction
10
Inputs
  • Net Form 4 buying (codes P and S), 180d-$4.1M · 20 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
49
Inputs
  • Funds adding, latest quarter234 · 92 pct, sector of 698
  • Congress net buyers, 365d-2 · 6 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
64
Inputs
  • Short interest, % of float+3.6% · 64 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ICLR filings, in plain words

Are Icon insiders buying or selling ICLR?

In the 180 days to 2026-10-28, Icon insiders were net sellers, a net $4.1M across purchases and sales reported on Form 4, by 10 sellers.

Have members of Congress traded ICLR?

Yes. In the year to 2026-10-28, 0 House members disclosed buying ICLR and 2 House members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-08-14.

Are there planned insider sales of ICLR?

Yes. 12 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $4.0M of stock; the latest, by RONAN MARTIN MURPHY, was filed 2026-09-17.

Read the full summary

In the 180 days to 2026-10-28, Icon insiders were net sellers of ICLR, a net $4.1M across purchases and sales reported on Form 4 by 10 sellers. None of the 42 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 0 members of Congress disclosed buying ICLR and 2 members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-08-14. Insiders filed 12 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $4.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies